Drug Profile


Alternative Names: A 64662

Latest Information Update: 24 Jan 2013

Price : $50

At a glance

  • Originator Abbott Laboratories
  • Class Antiglaucomas; Antihypertensives; Dipeptides; Heart failure therapies
  • Mechanism of Action Renin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Glaucoma; Heart failure; Hypertension

Most Recent Events

  • 31 Jul 2004 Discontinued - Preclinical for Glaucoma in USA (Topical)
  • 02 Jul 2001 No-Development-Reported for Glaucoma in USA (Topical)
  • 30 Nov 2000 Discontinued for Hypertension in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top